Extended-release formulations of oxybutynin and tolterodine exhibit similar central nervous system tolerability profiles : A subanalysis of data from the OPERA trial. Discussion
Identifieur interne :
000395 ( PascalFrancis/Corpus );
précédent :
000394;
suivant :
000396
Extended-release formulations of oxybutynin and tolterodine exhibit similar central nervous system tolerability profiles : A subanalysis of data from the OPERA trial. Discussion
Auteurs : Franklin M. Chu ;
Roger R. Dmochowski ;
Daniel J. Lama ;
Rodney U. Anderson ;
Peter K. Sand ;
Kelly MolpusSource :
-
American journal of obstetrics and gynecology [ 0002-9378 ] ; 2005.
RBID : Pascal:05-0375672
Descripteurs français
English descriptors
Abstract
Objective: This study was undertaken to compare the central nervous system (CNS) tolerability profiles of the extended-release formulations of oxybutynin chloride and tolterodine tartrate in the treatment of women with overactive bladder (OAB), as observed in the OPERA (Overactive bladder: Performance of Extended Release Agents) trial. Study design: The OPERA trial was a randomized, double-blind, active-control comparison of the efficacy and safety of extended-release oxybutynin (10 mg/d) and extended-release tolterodine (4 mg/d) given to 790 women with OAB for 12 weeks. The incidence of reported CNS events was compared between the treatment groups by using the Fisher exact test. Results: The incidence of CNS adverse events was 9% and 8% for the oxybutynin and tolterodine treatment groups, respectively. The difference between groups was not statistically significant. All reported CNS adverse events were rated as mild or moderate in severity. There were no serious treatment-related adverse events in either group, and discontinuation because of a CNS adverse event was infrequent. Conclusion: The extended-release formulations of oxybutynin and tolterodine were observed to be associated with a similar low incidence of CNS adverse events, which were mostly mild or moderate in severity.
Notice en format standard (ISO 2709)
Pour connaître la documentation sur le format Inist Standard.
| pA |
| A01 | 01 | 1 | | @0 0002-9378 |
|---|
| A02 | 01 | | | @0 AJOGAH |
|---|
| A03 | | 1 | | @0 Am. j. obstet. gynecol. |
|---|
| A05 | | | | @2 192 |
|---|
| A06 | | | | @2 6 |
|---|
| A08 | 01 | 1 | ENG | @1 Extended-release formulations of oxybutynin and tolterodine exhibit similar central nervous system tolerability profiles : A subanalysis of data from the OPERA trial. Discussion |
|---|
| A11 | 01 | 1 | | @1 CHU (Franklin M.) |
|---|
| A11 | 02 | 1 | | @1 DMOCHOWSKI (Roger R.) |
|---|
| A11 | 03 | 1 | | @1 LAMA (Daniel J.) |
|---|
| A11 | 04 | 1 | | @1 ANDERSON (Rodney U.) |
|---|
| A11 | 05 | 1 | | @1 SAND (Peter K.) |
|---|
| A11 | 06 | 1 | | @1 MOLPUS (Kelly) |
|---|
| A14 | 01 | | | @1 San Bernardino Urological Associates @2 San Bernardino, CA @3 USA @Z 1 aut. @Z 3 aut. |
|---|
| A14 | 02 | | | @1 Vanderbilt University Medical School @2 Nashville, TN @3 USA @Z 2 aut. |
|---|
| A14 | 03 | | | @1 Stanford University School of Medicine @2 Stanford, CA @3 USA @Z 4 aut. |
|---|
| A14 | 04 | | | @1 Northwestern University Medical School @2 Evanston, IL @3 USA @Z 5 aut. |
|---|
| A20 | | | | @1 1849-1855 |
|---|
| A21 | | | | @1 2005 |
|---|
| A23 | 01 | | | @0 ENG |
|---|
| A43 | 01 | | | @1 INIST @2 3053 @5 354000131538700110 |
|---|
| A44 | | | | @0 0000 @1 © 2005 INIST-CNRS. All rights reserved. |
|---|
| A45 | | | | @0 27 ref. |
|---|
| A47 | 01 | 1 | | @0 05-0375672 |
|---|
| A60 | | | | @1 P @2 C @3 AR @3 CT |
|---|
| A61 | | | | @0 A |
|---|
| A64 | 01 | 1 | | @0 American journal of obstetrics and gynecology |
|---|
| A66 | 01 | | | @0 USA |
|---|
| C01 | 01 | | ENG | @0 Objective: This study was undertaken to compare the central nervous system (CNS) tolerability profiles of the extended-release formulations of oxybutynin chloride and tolterodine tartrate in the treatment of women with overactive bladder (OAB), as observed in the OPERA (Overactive bladder: Performance of Extended Release Agents) trial. Study design: The OPERA trial was a randomized, double-blind, active-control comparison of the efficacy and safety of extended-release oxybutynin (10 mg/d) and extended-release tolterodine (4 mg/d) given to 790 women with OAB for 12 weeks. The incidence of reported CNS events was compared between the treatment groups by using the Fisher exact test. Results: The incidence of CNS adverse events was 9% and 8% for the oxybutynin and tolterodine treatment groups, respectively. The difference between groups was not statistically significant. All reported CNS adverse events were rated as mild or moderate in severity. There were no serious treatment-related adverse events in either group, and discontinuation because of a CNS adverse event was infrequent. Conclusion: The extended-release formulations of oxybutynin and tolterodine were observed to be associated with a similar low incidence of CNS adverse events, which were mostly mild or moderate in severity. |
|---|
| C02 | 01 | X | | @0 002B20 |
|---|
| C03 | 01 | X | FRE | @0 Oxybutynine @2 NK @2 FR @5 01 |
|---|
| C03 | 01 | X | ENG | @0 Oxybutynin @2 NK @2 FR @5 01 |
|---|
| C03 | 01 | X | SPA | @0 Oxibutinina @2 NK @2 FR @5 01 |
|---|
| C03 | 02 | X | FRE | @0 Libération @5 02 |
|---|
| C03 | 02 | X | ENG | @0 Release @5 02 |
|---|
| C03 | 02 | X | SPA | @0 Liberación @5 02 |
|---|
| C03 | 03 | X | FRE | @0 Formulation @5 03 |
|---|
| C03 | 03 | X | ENG | @0 Formulation @5 03 |
|---|
| C03 | 03 | X | SPA | @0 Formulación @5 03 |
|---|
| C03 | 04 | X | FRE | @0 Toltérodine @2 NK @2 FR @5 04 |
|---|
| C03 | 04 | X | ENG | @0 Tolterodine @2 NK @2 FR @5 04 |
|---|
| C03 | 04 | X | SPA | @0 Tolterodina @2 NK @2 FR @5 04 |
|---|
| C03 | 05 | X | FRE | @0 Système nerveux central @5 05 |
|---|
| C03 | 05 | X | ENG | @0 Central nervous system @5 05 |
|---|
| C03 | 05 | X | SPA | @0 Sistema nervioso central @5 05 |
|---|
| C03 | 06 | X | FRE | @0 Essai clinique @5 06 |
|---|
| C03 | 06 | X | ENG | @0 Clinical trial @5 06 |
|---|
| C03 | 06 | X | SPA | @0 Ensayo clínico @5 06 |
|---|
| C03 | 07 | X | FRE | @0 Discussion @5 08 |
|---|
| C03 | 07 | X | ENG | @0 Discussion @5 08 |
|---|
| C03 | 07 | X | SPA | @0 Discusión @5 08 |
|---|
| C03 | 08 | X | FRE | @0 Effet secondaire @5 09 |
|---|
| C03 | 08 | X | ENG | @0 Secondary effect @5 09 |
|---|
| C03 | 08 | X | SPA | @0 Efecto secundario @5 09 |
|---|
| C03 | 09 | X | FRE | @0 Gynécologie @5 11 |
|---|
| C03 | 09 | X | ENG | @0 Gynecology @5 11 |
|---|
| C03 | 09 | X | SPA | @0 Ginecología @5 11 |
|---|
| C03 | 10 | X | FRE | @0 Obstétrique @5 12 |
|---|
| C03 | 10 | X | ENG | @0 Obstetrics @5 12 |
|---|
| C03 | 10 | X | SPA | @0 Obstétrico @5 12 |
|---|
| C07 | 01 | X | FRE | @0 Antagoniste @5 37 |
|---|
| C07 | 01 | X | ENG | @0 Antagonist @5 37 |
|---|
| C07 | 01 | X | SPA | @0 Antagonista @5 37 |
|---|
| C07 | 02 | X | FRE | @0 Parasympatholytique @5 38 |
|---|
| C07 | 02 | X | ENG | @0 Parasympatholytic @5 38 |
|---|
| C07 | 02 | X | SPA | @0 Parasimpatolítico @5 38 |
|---|
| C07 | 03 | X | FRE | @0 Récepteur cholinergique @5 39 |
|---|
| C07 | 03 | X | ENG | @0 Cholinergic receptor @5 39 |
|---|
| C07 | 03 | X | SPA | @0 Receptor colinérgico @5 39 |
|---|
| C07 | 04 | X | FRE | @0 Récepteur muscarinique @5 40 |
|---|
| C07 | 04 | X | ENG | @0 Muscarinic receptor @5 40 |
|---|
| C07 | 04 | X | SPA | @0 Receptor muscarínico @5 40 |
|---|
| N21 | | | | @1 262 |
|---|
| N44 | 01 | | | @1 OTO |
|---|
| N82 | | | | @1 OTO |
|---|
|
|---|
| pR |
| A30 | 01 | 1 | ENG | @1 Annual Meeting of the Central Association of Obstetricians and Gynecologists @2 71 @3 Washington, DC USA @4 2004-10-13 |
|---|
|
|---|
Format Inist (serveur)
| NO : | PASCAL 05-0375672 INIST |
|---|
| ET : | Extended-release formulations of oxybutynin and tolterodine exhibit similar central nervous system tolerability profiles : A subanalysis of data from the OPERA trial. Discussion |
|---|
| AU : | CHU (Franklin M.); DMOCHOWSKI (Roger R.); LAMA (Daniel J.); ANDERSON (Rodney U.); SAND (Peter K.); MOLPUS (Kelly) |
|---|
| AF : | San Bernardino Urological Associates/San Bernardino, CA/Etats-Unis (1 aut., 3 aut.); Vanderbilt University Medical School/Nashville, TN/Etats-Unis (2 aut.); Stanford University School of Medicine/Stanford, CA/Etats-Unis (4 aut.); Northwestern University Medical School/Evanston, IL/Etats-Unis (5 aut.) |
|---|
| DT : | Publication en série; Congrès; Article; Commentaire; Niveau analytique |
|---|
| SO : | American journal of obstetrics and gynecology; ISSN 0002-9378; Coden AJOGAH; Etats-Unis; Da. 2005; Vol. 192; No. 6; Pp. 1849-1855; Bibl. 27 ref. |
|---|
| LA : | Anglais |
|---|
| EA : | Objective: This study was undertaken to compare the central nervous system (CNS) tolerability profiles of the extended-release formulations of oxybutynin chloride and tolterodine tartrate in the treatment of women with overactive bladder (OAB), as observed in the OPERA (Overactive bladder: Performance of Extended Release Agents) trial. Study design: The OPERA trial was a randomized, double-blind, active-control comparison of the efficacy and safety of extended-release oxybutynin (10 mg/d) and extended-release tolterodine (4 mg/d) given to 790 women with OAB for 12 weeks. The incidence of reported CNS events was compared between the treatment groups by using the Fisher exact test. Results: The incidence of CNS adverse events was 9% and 8% for the oxybutynin and tolterodine treatment groups, respectively. The difference between groups was not statistically significant. All reported CNS adverse events were rated as mild or moderate in severity. There were no serious treatment-related adverse events in either group, and discontinuation because of a CNS adverse event was infrequent. Conclusion: The extended-release formulations of oxybutynin and tolterodine were observed to be associated with a similar low incidence of CNS adverse events, which were mostly mild or moderate in severity. |
|---|
| CC : | 002B20 |
|---|
| FD : | Oxybutynine; Libération; Formulation; Toltérodine; Système nerveux central; Essai clinique; Discussion; Effet secondaire; Gynécologie; Obstétrique |
|---|
| FG : | Antagoniste; Parasympatholytique; Récepteur cholinergique; Récepteur muscarinique |
|---|
| ED : | Oxybutynin; Release; Formulation; Tolterodine; Central nervous system; Clinical trial; Discussion; Secondary effect; Gynecology; Obstetrics |
|---|
| EG : | Antagonist; Parasympatholytic; Cholinergic receptor; Muscarinic receptor |
|---|
| SD : | Oxibutinina; Liberación; Formulación; Tolterodina; Sistema nervioso central; Ensayo clínico; Discusión; Efecto secundario; Ginecología; Obstétrico |
|---|
| LO : | INIST-3053.354000131538700110 |
|---|
| ID : | 05-0375672 |
|---|
Links to Exploration step
Pascal:05-0375672
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Extended-release formulations of oxybutynin and tolterodine exhibit similar central nervous system tolerability profiles : A subanalysis of data from the OPERA trial. Discussion</title>
<author><name sortKey="Chu, Franklin M" sort="Chu, Franklin M" uniqKey="Chu F" first="Franklin M." last="Chu">Franklin M. Chu</name>
<affiliation><inist:fA14 i1="01"><s1>San Bernardino Urological Associates</s1>
<s2>San Bernardino, CA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14><author><name sortKey="Dmochowski, Roger R" sort="Dmochowski, Roger R" uniqKey="Dmochowski R" first="Roger R." last="Dmochowski">Roger R. Dmochowski</name>
<affiliation><inist:fA14 i1="02"><s1>Vanderbilt University Medical School</s1>
<s2>Nashville, TN</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14><author><name sortKey="Lama, Daniel J" sort="Lama, Daniel J" uniqKey="Lama D" first="Daniel J." last="Lama">Daniel J. Lama</name>
<affiliation><inist:fA14 i1="01"><s1>San Bernardino Urological Associates</s1>
<s2>San Bernardino, CA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14><author><name sortKey="Anderson, Rodney U" sort="Anderson, Rodney U" uniqKey="Anderson R" first="Rodney U." last="Anderson">Rodney U. Anderson</name>
<affiliation><inist:fA14 i1="03"><s1>Stanford University School of Medicine</s1>
<s2>Stanford, CA</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14><author><name sortKey="Sand, Peter K" sort="Sand, Peter K" uniqKey="Sand P" first="Peter K." last="Sand">Peter K. Sand</name>
<affiliation><inist:fA14 i1="04"><s1>Northwestern University Medical School</s1>
<s2>Evanston, IL</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14><author><name sortKey="Molpus, Kelly" sort="Molpus, Kelly" uniqKey="Molpus K" first="Kelly" last="Molpus">Kelly Molpus</name>
</author><publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">05-0375672</idno>
<date when="2005">2005</date>
<idno type="stanalyst">PASCAL 05-0375672 INIST</idno>
<idno type="RBID">Pascal:05-0375672</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000395</idno>
</publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Extended-release formulations of oxybutynin and tolterodine exhibit similar central nervous system tolerability profiles : A subanalysis of data from the OPERA trial. Discussion</title>
<author><name sortKey="Chu, Franklin M" sort="Chu, Franklin M" uniqKey="Chu F" first="Franklin M." last="Chu">Franklin M. Chu</name>
<affiliation><inist:fA14 i1="01"><s1>San Bernardino Urological Associates</s1>
<s2>San Bernardino, CA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14><author><name sortKey="Dmochowski, Roger R" sort="Dmochowski, Roger R" uniqKey="Dmochowski R" first="Roger R." last="Dmochowski">Roger R. Dmochowski</name>
<affiliation><inist:fA14 i1="02"><s1>Vanderbilt University Medical School</s1>
<s2>Nashville, TN</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14><author><name sortKey="Lama, Daniel J" sort="Lama, Daniel J" uniqKey="Lama D" first="Daniel J." last="Lama">Daniel J. Lama</name>
<affiliation><inist:fA14 i1="01"><s1>San Bernardino Urological Associates</s1>
<s2>San Bernardino, CA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14><author><name sortKey="Anderson, Rodney U" sort="Anderson, Rodney U" uniqKey="Anderson R" first="Rodney U." last="Anderson">Rodney U. Anderson</name>
<affiliation><inist:fA14 i1="03"><s1>Stanford University School of Medicine</s1>
<s2>Stanford, CA</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14><author><name sortKey="Sand, Peter K" sort="Sand, Peter K" uniqKey="Sand P" first="Peter K." last="Sand">Peter K. Sand</name>
<affiliation><inist:fA14 i1="04"><s1>Northwestern University Medical School</s1>
<s2>Evanston, IL</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14><author><name sortKey="Molpus, Kelly" sort="Molpus, Kelly" uniqKey="Molpus K" first="Kelly" last="Molpus">Kelly Molpus</name>
</author><series><title level="j" type="main">American journal of obstetrics and gynecology</title>
<title level="j" type="abbreviated">Am. j. obstet. gynecol.</title>
<idno type="ISSN">0002-9378</idno>
<imprint><date when="2005">2005</date>
</imprint><seriesStmt><title level="j" type="main">American journal of obstetrics and gynecology</title>
<title level="j" type="abbreviated">Am. j. obstet. gynecol.</title>
<idno type="ISSN">0002-9378</idno>
</seriesStmt><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Central nervous system</term>
<term>Clinical trial</term>
<term>Discussion</term>
<term>Formulation</term>
<term>Gynecology</term>
<term>Obstetrics</term>
<term>Oxybutynin</term>
<term>Release</term>
<term>Secondary effect</term>
<term>Tolterodine</term>
</keywords><keywords scheme="Pascal" xml:lang="fr"><term>Oxybutynine</term>
<term>Libération</term>
<term>Formulation</term>
<term>Toltérodine</term>
<term>Système nerveux central</term>
<term>Essai clinique</term>
<term>Discussion</term>
<term>Effet secondaire</term>
<term>Gynécologie</term>
<term>Obstétrique</term>
</keywords><front><div type="abstract" xml:lang="en">Objective: This study was undertaken to compare the central nervous system (CNS) tolerability profiles of the extended-release formulations of oxybutynin chloride and tolterodine tartrate in the treatment of women with overactive bladder (OAB), as observed in the OPERA (Overactive bladder: Performance of Extended Release Agents) trial. Study design: The OPERA trial was a randomized, double-blind, active-control comparison of the efficacy and safety of extended-release oxybutynin (10 mg/d) and extended-release tolterodine (4 mg/d) given to 790 women with OAB for 12 weeks. The incidence of reported CNS events was compared between the treatment groups by using the Fisher exact test. Results: The incidence of CNS adverse events was 9% and 8% for the oxybutynin and tolterodine treatment groups, respectively. The difference between groups was not statistically significant. All reported CNS adverse events were rated as mild or moderate in severity. There were no serious treatment-related adverse events in either group, and discontinuation because of a CNS adverse event was infrequent. Conclusion: The extended-release formulations of oxybutynin and tolterodine were observed to be associated with a similar low incidence of CNS adverse events, which were mostly mild or moderate in severity.</div>
</front><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0002-9378</s0>
</fA01><fA02 i1="01"><s0>AJOGAH</s0>
</fA02><fA03 i2="1"><s0>Am. j. obstet. gynecol.</s0>
</fA03><fA05><s2>192</s2>
</fA05><fA08 i1="01" i2="1" l="ENG"><s1>Extended-release formulations of oxybutynin and tolterodine exhibit similar central nervous system tolerability profiles : A subanalysis of data from the OPERA trial. Discussion</s1>
</fA08><fA11 i1="01" i2="1"><s1>CHU (Franklin M.)</s1>
</fA11><fA11 i1="02" i2="1"><s1>DMOCHOWSKI (Roger R.)</s1>
</fA11><fA11 i1="03" i2="1"><s1>LAMA (Daniel J.)</s1>
</fA11><fA11 i1="04" i2="1"><s1>ANDERSON (Rodney U.)</s1>
</fA11><fA11 i1="05" i2="1"><s1>SAND (Peter K.)</s1>
</fA11><fA11 i1="06" i2="1"><s1>MOLPUS (Kelly)</s1>
</fA11><fA14 i1="01"><s1>San Bernardino Urological Associates</s1>
<s2>San Bernardino, CA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</fA14><fA14 i1="02"><s1>Vanderbilt University Medical School</s1>
<s2>Nashville, TN</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</fA14><fA14 i1="03"><s1>Stanford University School of Medicine</s1>
<s2>Stanford, CA</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</fA14><fA14 i1="04"><s1>Northwestern University Medical School</s1>
<s2>Evanston, IL</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</fA14><fA20><s1>1849-1855</s1>
</fA20><fA21><s1>2005</s1>
</fA21><fA23 i1="01"><s0>ENG</s0>
</fA23><fA43 i1="01"><s1>INIST</s1>
<s2>3053</s2>
<s5>354000131538700110</s5>
</fA43><fA44><s0>0000</s0>
<s1>© 2005 INIST-CNRS. All rights reserved.</s1>
</fA44><fA45><s0>27 ref.</s0>
</fA45><fA47 i1="01" i2="1"><s0>05-0375672</s0>
</fA47><fA60><s1>P</s1>
<s2>C</s2>
<s3>AR</s3>
<s3>CT</s3>
</fA60><fA64 i1="01" i2="1"><s0>American journal of obstetrics and gynecology</s0>
</fA64><fA66 i1="01"><s0>USA</s0>
</fA66><fC01 i1="01" l="ENG"><s0>Objective: This study was undertaken to compare the central nervous system (CNS) tolerability profiles of the extended-release formulations of oxybutynin chloride and tolterodine tartrate in the treatment of women with overactive bladder (OAB), as observed in the OPERA (Overactive bladder: Performance of Extended Release Agents) trial. Study design: The OPERA trial was a randomized, double-blind, active-control comparison of the efficacy and safety of extended-release oxybutynin (10 mg/d) and extended-release tolterodine (4 mg/d) given to 790 women with OAB for 12 weeks. The incidence of reported CNS events was compared between the treatment groups by using the Fisher exact test. Results: The incidence of CNS adverse events was 9% and 8% for the oxybutynin and tolterodine treatment groups, respectively. The difference between groups was not statistically significant. All reported CNS adverse events were rated as mild or moderate in severity. There were no serious treatment-related adverse events in either group, and discontinuation because of a CNS adverse event was infrequent. Conclusion: The extended-release formulations of oxybutynin and tolterodine were observed to be associated with a similar low incidence of CNS adverse events, which were mostly mild or moderate in severity.</s0>
</fC01><fC02 i1="01" i2="X"><s0>002B20</s0>
</fC02><fC03 i1="01" i2="X" l="FRE"><s0>Oxybutynine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>01</s5>
</fC03><fC03 i1="01" i2="X" l="ENG"><s0>Oxybutynin</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>01</s5>
</fC03><fC03 i1="01" i2="X" l="SPA"><s0>Oxibutinina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>01</s5>
</fC03><fC03 i1="02" i2="X" l="FRE"><s0>Libération</s0>
<s5>02</s5>
</fC03><fC03 i1="02" i2="X" l="ENG"><s0>Release</s0>
<s5>02</s5>
</fC03><fC03 i1="02" i2="X" l="SPA"><s0>Liberación</s0>
<s5>02</s5>
</fC03><fC03 i1="03" i2="X" l="FRE"><s0>Formulation</s0>
<s5>03</s5>
</fC03><fC03 i1="03" i2="X" l="ENG"><s0>Formulation</s0>
<s5>03</s5>
</fC03><fC03 i1="03" i2="X" l="SPA"><s0>Formulación</s0>
<s5>03</s5>
</fC03><fC03 i1="04" i2="X" l="FRE"><s0>Toltérodine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03><fC03 i1="04" i2="X" l="ENG"><s0>Tolterodine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03><fC03 i1="04" i2="X" l="SPA"><s0>Tolterodina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03><fC03 i1="05" i2="X" l="FRE"><s0>Système nerveux central</s0>
<s5>05</s5>
</fC03><fC03 i1="05" i2="X" l="ENG"><s0>Central nervous system</s0>
<s5>05</s5>
</fC03><fC03 i1="05" i2="X" l="SPA"><s0>Sistema nervioso central</s0>
<s5>05</s5>
</fC03><fC03 i1="06" i2="X" l="FRE"><s0>Essai clinique</s0>
<s5>06</s5>
</fC03><fC03 i1="06" i2="X" l="ENG"><s0>Clinical trial</s0>
<s5>06</s5>
</fC03><fC03 i1="06" i2="X" l="SPA"><s0>Ensayo clínico</s0>
<s5>06</s5>
</fC03><fC03 i1="07" i2="X" l="FRE"><s0>Discussion</s0>
<s5>08</s5>
</fC03><fC03 i1="07" i2="X" l="ENG"><s0>Discussion</s0>
<s5>08</s5>
</fC03><fC03 i1="07" i2="X" l="SPA"><s0>Discusión</s0>
<s5>08</s5>
</fC03><fC03 i1="08" i2="X" l="FRE"><s0>Effet secondaire</s0>
<s5>09</s5>
</fC03><fC03 i1="08" i2="X" l="ENG"><s0>Secondary effect</s0>
<s5>09</s5>
</fC03><fC03 i1="08" i2="X" l="SPA"><s0>Efecto secundario</s0>
<s5>09</s5>
</fC03><fC03 i1="09" i2="X" l="FRE"><s0>Gynécologie</s0>
<s5>11</s5>
</fC03><fC03 i1="09" i2="X" l="ENG"><s0>Gynecology</s0>
<s5>11</s5>
</fC03><fC03 i1="09" i2="X" l="SPA"><s0>Ginecología</s0>
<s5>11</s5>
</fC03><fC03 i1="10" i2="X" l="FRE"><s0>Obstétrique</s0>
<s5>12</s5>
</fC03><fC03 i1="10" i2="X" l="ENG"><s0>Obstetrics</s0>
<s5>12</s5>
</fC03><fC03 i1="10" i2="X" l="SPA"><s0>Obstétrico</s0>
<s5>12</s5>
</fC03><fC07 i1="01" i2="X" l="FRE"><s0>Antagoniste</s0>
<s5>37</s5>
</fC07><fC07 i1="01" i2="X" l="ENG"><s0>Antagonist</s0>
<s5>37</s5>
</fC07><fC07 i1="01" i2="X" l="SPA"><s0>Antagonista</s0>
<s5>37</s5>
</fC07><fC07 i1="02" i2="X" l="FRE"><s0>Parasympatholytique</s0>
<s5>38</s5>
</fC07><fC07 i1="02" i2="X" l="ENG"><s0>Parasympatholytic</s0>
<s5>38</s5>
</fC07><fC07 i1="02" i2="X" l="SPA"><s0>Parasimpatolítico</s0>
<s5>38</s5>
</fC07><fC07 i1="03" i2="X" l="FRE"><s0>Récepteur cholinergique</s0>
<s5>39</s5>
</fC07><fC07 i1="03" i2="X" l="ENG"><s0>Cholinergic receptor</s0>
<s5>39</s5>
</fC07><fC07 i1="03" i2="X" l="SPA"><s0>Receptor colinérgico</s0>
<s5>39</s5>
</fC07><fC07 i1="04" i2="X" l="FRE"><s0>Récepteur muscarinique</s0>
<s5>40</s5>
</fC07><fC07 i1="04" i2="X" l="ENG"><s0>Muscarinic receptor</s0>
<s5>40</s5>
</fC07><fC07 i1="04" i2="X" l="SPA"><s0>Receptor muscarínico</s0>
<s5>40</s5>
</fC07><fN21><s1>262</s1>
</fN21><fN44 i1="01"><s1>OTO</s1>
</fN44><fN82><s1>OTO</s1>
</fN82><pR><fA30 i1="01" i2="1" l="ENG"><s1>Annual Meeting of the Central Association of Obstetricians and Gynecologists</s1>
<s2>71</s2>
<s3>Washington, DC USA</s3>
<s4>2004-10-13</s4>
</fA30><server><NO>PASCAL 05-0375672 INIST</NO>
<ET>Extended-release formulations of oxybutynin and tolterodine exhibit similar central nervous system tolerability profiles : A subanalysis of data from the OPERA trial. Discussion</ET>
<AU>CHU (Franklin M.); DMOCHOWSKI (Roger R.); LAMA (Daniel J.); ANDERSON (Rodney U.); SAND (Peter K.); MOLPUS (Kelly)</AU>
<AF>San Bernardino Urological Associates/San Bernardino, CA/Etats-Unis (1 aut., 3 aut.); Vanderbilt University Medical School/Nashville, TN/Etats-Unis (2 aut.); Stanford University School of Medicine/Stanford, CA/Etats-Unis (4 aut.); Northwestern University Medical School/Evanston, IL/Etats-Unis (5 aut.)</AF>
<DT>Publication en série; Congrès; Article; Commentaire; Niveau analytique</DT>
<SO>American journal of obstetrics and gynecology; ISSN 0002-9378; Coden AJOGAH; Etats-Unis; Da. 2005; Vol. 192; No. 6; Pp. 1849-1855; Bibl. 27 ref.</SO>
<LA>Anglais</LA>
<EA>Objective: This study was undertaken to compare the central nervous system (CNS) tolerability profiles of the extended-release formulations of oxybutynin chloride and tolterodine tartrate in the treatment of women with overactive bladder (OAB), as observed in the OPERA (Overactive bladder: Performance of Extended Release Agents) trial. Study design: The OPERA trial was a randomized, double-blind, active-control comparison of the efficacy and safety of extended-release oxybutynin (10 mg/d) and extended-release tolterodine (4 mg/d) given to 790 women with OAB for 12 weeks. The incidence of reported CNS events was compared between the treatment groups by using the Fisher exact test. Results: The incidence of CNS adverse events was 9% and 8% for the oxybutynin and tolterodine treatment groups, respectively. The difference between groups was not statistically significant. All reported CNS adverse events were rated as mild or moderate in severity. There were no serious treatment-related adverse events in either group, and discontinuation because of a CNS adverse event was infrequent. Conclusion: The extended-release formulations of oxybutynin and tolterodine were observed to be associated with a similar low incidence of CNS adverse events, which were mostly mild or moderate in severity.</EA>
<CC>002B20</CC>
<FD>Oxybutynine; Libération; Formulation; Toltérodine; Système nerveux central; Essai clinique; Discussion; Effet secondaire; Gynécologie; Obstétrique</FD>
<FG>Antagoniste; Parasympatholytique; Récepteur cholinergique; Récepteur muscarinique</FG>
<ED>Oxybutynin; Release; Formulation; Tolterodine; Central nervous system; Clinical trial; Discussion; Secondary effect; Gynecology; Obstetrics</ED>
<EG>Antagonist; Parasympatholytic; Cholinergic receptor; Muscarinic receptor</EG>
<SD>Oxibutinina; Liberación; Formulación; Tolterodina; Sistema nervioso central; Ensayo clínico; Discusión; Efecto secundario; Ginecología; Obstétrico</SD>
<LO>INIST-3053.354000131538700110</LO>
<ID>05-0375672</ID>
</server>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Musique/explor/OperaV1/Data/PascalFrancis/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000395 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000395 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Musique
|area= OperaV1
|flux= PascalFrancis
|étape= Corpus
|type= RBID
|clé= Pascal:05-0375672
|texte= Extended-release formulations of oxybutynin and tolterodine exhibit similar central nervous system tolerability profiles : A subanalysis of data from the OPERA trial. Discussion
}}
| This area was generated with Dilib version V0.6.21.
Data generation: Thu Apr 14 14:59:05 2016. Site generation: Thu Jan 4 23:09:23 2024 |  |
